Michael F. Mahoney

This profile gathers the share dealings of Michael F. Mahoney across 3 companies, led by Boston Scientific Corp, CVS HEALTH Corp and Baxter International Inc. We count 69 filings; the first trade dates from 1 January 2016 and the latest from 3 August 2026.

On the open market, the record shows 3 purchases worth €10.2M and 6 sales worth €34.7M. Netting one side against the other leaves €24.5M of net selling. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 11 share grants and 38 option exercises. 2026 to date brings 1 purchase and no sales.

A typical purchase (the median) is worth €1.9M. 2 out of 3 purchases came within 30 days of a purchase by at least one other insider of the same company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The newest entry dates from 5 August 2026: an open-market purchase of €7.8M, in Boston Scientific Corp. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.